GI Cancers
Nigro regiment | 1983 | Anal Cancer |
RTOG 98-11 trial, mitomycin vs cis | 2008 | Anal Cancer |
ClarIDHy trial | 2020 | Cholangiocarcinoma - advanced |
FOLFIRI vs 5FU in metastatic CRC | 2000 | Colon - advanced |
FOLFOX vs 5-FU in metastatic CRC | 2000 | Colon - advanced |
FOLFIRI PLUS Bev in mCRC | 2004 | Colon - advanced |
CRYSTAL trial | 2009 | Colon - advanced |
FIRE Trial (Final Analysis) | 2014 | Colon - advanced |
PRIME trial | 2014 | Colon - advanced |
CALGB80405 trial | 2017 | Colon - advanced |
MOSAIC trial | 2004 | Colon - perioperative |
UNICANCER-PRODIGE 23 | 2021 | Colon - perioperative |
RAPIDO trial | 2021 | Colon - perioperative |
ATTRACTION 2 TRIAL | 2017 | Esophageal - advanced |
ATTRACTION-3 Trial | 2019 | Esophageal - advanced |
KEYNOTE 181 Trial | 2020 | Esophageal - advanced |
KEYNOTE-590 | 2021 | Esophageal - advanced |
CROSS Trial | 2012 | Esophageal - perioperative |
Checkmate 577 | 2021 | Esophageal - perioperative |
ACOSOG Z9001 trial | 2009 | GIST - adjuvant |
SSG XVIII trial | 2012 | GIST - adjuvant |
Intergroup EORTC 62024 trial | 2015 | GIST - adjuvant |
EORTC 62005 trial | 2004 | GIST - metastatic |
Sunitinib trial | 2006 | GIST - metastatic |
US Intergroup trial, SWOG0033/CLAGB1501105 | 2008 | GIST - metastatic |
MetaGIST group trial | 2010 | GIST - metastatic |
Regorafenib trial | 2013 | GIST - metastatic |
Avapritinib/NAVIGATOR trial | 2020 | GIST - metastatic |
INVICTUS trial | 2020 | GIST - metastatic |
TOGA Trial | 2010 | Gastric - advanced |
REGARD trial | 2014 | Gastric - advanced |
RAINBOW | 2014 | Gastric - advanced |
DESTINY-Gastric01 | 2020 | Gastric - advanced |
KEYNOTE-811 trial | 2021 | Gastric - advanced |
Checkmate 649 trial | 2021 | Gastric - advanced |
FIGHT | 2021 | Gastric - advanced |
MacDonald study - INT0116 (SWOG 9008) | 2001 | Gastric - perioperative |
MAGIC trial | 2006 | Gastric - perioperative |
CLASSIC trial | 2012 | Gastric - perioperative |
FLOT | 2019 | Gastric - perioperative |
Resorce Trial | 2016 | HCC |
Checkmate 040 | 2017 | HCC |
SHARP trial, Sora vs pbo | 2018 | HCC |
Keynote 224 | 2018 | HCC |
Celestial Trial, cabo vs pbo | 2018 | HCC |
Len vs Sora trial | 2018 | HCC |
IMbrave 150, atezo/bev vs sora | 2020 | HCC |
Checkmate 040 - Update | 2020 | HCC |
PROMID trial, octreotide vs pbo | 2009 | NET |
SUNITINIB NET, sun vs pbo | 2011 | NET |
CLARINET trial, lancreotide vs pbo | 2014 | NET |
RADIANT 4 trial | 2016 | NET |
NETTER-1 Trial | 2017 | NET |
Gemcitabine VS 5-FU TRIAL | 1997 | Pancreas - advanced |
PRODIGE 4/ACCORD 11 trial | 2011 | Pancreas - advanced |
MPACT trial | 2013 | Pancreas - advanced |
POLO Trial | 2019 | Pancreas - advanced |
GITSG trial | 1985 | Pancreas - perioperative |
CONKO-001 trial | 2007 | Pancreas - perioperative |
ESPAC-4 trial | 2017 | Pancreas - perioperative |
PRODIGE 24 trial | 2018 | Pancreas - perioperative |
APACT trial | 2019 | Pancreas - perioperative |
ESPAC-5F | 2020 | Pancreas - perioperative |
PREOPANC Trial | 2020 | Pancreas - perioperative |
SWOG 1505 trial | 2021 | Pancreas - perioperative |
TME trial | 1986 | Rectal cancer - LARC |
NSABP R-01, first adj chemo in LARC | 1988 | Rectal cancer - LARC |
RT before TME trial | 2001 | Rectal cancer - LARC |
Preop vs postop chemo | 2004 | Rectal cancer - LARC |
NSABP R-04 trial | 2004 | Rectal cancer - LARC |
TNT trial | 2010 | Rectal cancer - LARC |
Rektum-III trial, cape vs 5FU | 2012 | Rectal cancer - LARC |
CRT+MFOLFOX | 2016 | Rectal cancer - LARC |
Neadjuvant Dostarlimab in dMMR LARC | 2022 | Rectal cancer - LARC |
Nigro regiment
Nigro ND et al, Cancer, 1983 PMID: 6831348
Anal Cancer
Background. Single-institution study at Wayne State included 28 patients with local anal SCC to receive chemoradiation therapy followed by surgery.
RT: 30 Gy in 15 fx via AP/PA fields to the pelvis, medial inguinal LN and anal canal
Chemo: 5-FU (1000mg/m2/day) x 4 days + MMC (single 15 mg/m2 bolus)
Survgery: abdominal perenial resection (APR).
Initially APR planned in all pts; however, since 5/6 initial patients had no residual tumors in APR specimen
APR was then reserved as salvage treatment
Overall, 86% (24/28) pts had a clinical CR to combined chemoradiation therapy
Conclusion. The experience with concurrent chemoradiation convinced authors that it is effective enough not to require abdominal perenial resection.
Summarized by Veli Bakalov, MD